Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer ...

skin or joint infections and severe leucopenia Etanercept (Enbrel®) Injection site reactions and upper respiratory tract infections Serious bacterial infections, unusual infections (tuberculosis ...

She started treatment with etanercept (Enbrel ®) 1 month previously ... common adverse effect of this treatment was injection site reaction (ISR). This can occur in up to 49% of patients and ...

The FDA noted that 82 people taking these glatiramer acetate medications required ER visits or hospitalizations, and 6 others ...

FDA adds boxed warning to a multiple sclerosis drug, citing rare but severe risk. Today, the FDA issued a warning about the risk of anaphylaxis, a rare but life-threatening allergic reaction ...

Jan 22 (Reuters) - The U.S. Food and Drug Administration on Wednesday warned about the risk of a rare but serious allergic reaction with the use of some multiple sclerosis drugs including Teva's ...

Alpha-gal syndrome was discovered because of unexpected severe drug reactions, including anaphylaxis, in some patients who took cetuximab, a cancer drug. A 2008 study found antibodies to alpha-gal ...

but molecules with three-dimensional complexity usually perform better as drugs. Reactions that quickly make molecules with 3D complexity are not as efficient because they require specialized ...

The U.S. Food and Drug Administration on Wednesday warned about the risk of a rare but serious allergic reaction with the use of multiple sclerosis drugs including Teva's Copaxone. The health ...

They include such popular medications as Jardiance (diabetes), Enbrel (rheumatoid arthritis) and Eliquis (blood clots). In its last days, the Biden administration targeted another 15 Part D drugs ...

The appeals court ruling blocks Sandoz from producing a biosimilar of Enbrel (etanercept ... US health system that could be spent on newer drugs as well as widening access to biologic medicines.